COMMUNIQUÉS West-GlobeNewswire

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
07/08/2026
Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year Purified Cortrophin ® Gel net revenues of $117.1 million, an increase of 43.5% year-over-year Quarterly GAAP net income available to common [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
07/08/2026
Tokyo, Japan and Cambridge, UK, 7 August 202 6 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter ended 30 June [...]
Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years
07/08/2026
MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virus Approval further strengthens MVA-BN’s position in supporting global [...]
National Health Sanitary Association Announces United Nations Procurement and Partnership Registration
07/08/2026
Washington State-based public health organization expands international cooperation framework for disease prevention, health education, humanitarian assistance and community health development. WASHINGTON, Aug. 07, 2026 [...]
CancerVax Achieves Major Milestone in Activating Human Killer T-Cells Against Cancer
07/08/2026
In-vitro studies confirmed that the Company’s revolutionary therapy successfully disguised liver cancer cells as virally infected cells and activated pre-existing human antiviral Killer T-cells Lehi Utah, Aug. 06, 2026 [...]
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
07/08/2026
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , (“BlossomHill Therapeutics”), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop [...]
Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering
07/08/2026
THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced [...]
Better U Expands 2026 Patient Eligibility, Safety and Treatment Access Information for At-Home Ketamine Therapy
07/08/2026
Online eligibility screening, off-label compounded oral ketamine and licensed pharmacy fulfillment explained, with SPRAVATO esketamine offered separately WEST HOLLYWOOD, Calif.,, Aug. 06, 2026 (GLOBE NEWSWIRE) -- [...]
Tango Therapeutics Announces Executive Chair Transition
07/08/2026
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today [...]
Biogen Completes Acquisition of RayThera Inc.
07/08/2026
Lead program now in Phase 1 development CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology [...]
BioStem Technologies Announces Nasdaq Uplisting
06/08/2026
Trading to Commence on August 7, 2026 POMPANO BEACH, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the [...]
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
06/08/2026
BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will hold investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 [...]
VitalHub Announces Normal Course Issuer Bid
06/08/2026
TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (“VitalHub” or the “Company”) announced today that the Toronto Stock Exchange (the "Exchange") has accepted a notice filed by VitalHub of [...]
VitalHub Reports Second Quarter 2026 Results
06/08/2026
Annual Recurring Revenue (“ARR”)⁽¹⁾ up 28% YoY to $101.5 million Total Revenue up 33% YoY to $31.7 million Adjusted EBITDA⁽¹⁾ up 29% YoY to $8.2 million TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI [...]
Sanuwave Announces Q2 FY2026 Financial Results
06/08/2026
Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 [...]
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
06/08/2026
Approval Offers New Hope for Patients with Anti-PD-1 Refractory Melanoma Silver Spring, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev ( [...]
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
06/08/2026
WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Cellectis Reports Financial Results for the Second Quarter 2026
06/08/2026
Lasme-cel: Pivotal Phase 2 in r/r B-ALL (BALLI-01) FDA RMAT designation received for lasme-cel Full Phase 1 clinical data from the BALLI-01 trial presented at EHA 2026 Pivotal Phase 2 first interim analysis expected in [...]
Cellectis publie ses résultats financiers du deuxième trimestre 2026
06/08/2026
Lasmé-cel: phase 2 pivotale dans la LAL-B en rechute ou réfractaire (étude BALLI-01) Lasmé-cel a reçu le statut RMAT de la FDA Résultats complets de phase 1 pour lasmé-cel présentés au congrès annuel de l’EHA 2026 [...]

Pages